Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + FLAG/CLAG for Frontline Therapy of Secondary AML
NCT05780879Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by University of Michigan Rogel Cancer Center. Started Jun 2024; status: terminated.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05780879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780879.